Intrommune Therapeutics
Intrommune Therapeutics, a specialty biopharmaceutical firm, innovates safe, convenient solutions for food allergies via its Oral Mucosal Immunotherapy platform.
Founded
2015Intrommune Therapeutics, a specialty biopharmaceutical firm, innovates safe, convenient solutions for food allergies via its Oral Mucosal Immunotherapy platform.
Intrommune Therapeutics, founded as a specialty biopharmaceutical company, focuses on developing safe, convenient, and effective treatments for individuals suffering from food allergies. Their core mission is to enable people with food allergies to live without fear through innovative health solutions. The company's flagship product is based on their Oral Mucosal Immunotherapy (OMIT) platform, which integrates seamlessly into daily routines and is grounded in established immunotherapy principles.
Notable affiliated individuals and investors include experts in immunotherapy and biotechnology sectors, though specific names are not provided. Key achievements include advancing their OMIT platform to clinical stages, demonstrating its potential as a disease-modifying treatment with long-term efficacy. Intrommune Therapeutics has made a significant impact by addressing a critical need for safer and more effective food allergy therapies, potentially transforming the lives of millions of allergy sufferers.
Companies similar to Intrommune Therapeutics include Alladapt Immunotherapeutics, IM Therapeutics, Tunitas Therapeutics and Rise Therapeutics.
Intrommune Therapeutics was founded in 2015.
Intrommune Therapeutics' headquarters is located in New York City, NY, US.
As of Feb 8, 2022, Intrommune Therapeutics has disclosed funding of $6.2M (USD). Undisclosed round amounts are excluded.
Intrommune Therapeutics has 17 employees as of Feb 5, 2024.
Rise Therapeutics
